Subscribe to ROADMAP newsletter

Alzheimer’s disease is on the rise in our ageing population, and new, effective treatments are urgently needed. Currently, the safety and benefits to patients of potential treatments are assessed in strictly-controlled clinical trials. However, clinical trials do not reflect the effects of treatments on patients in their daily lives in the ‘real world’. The ROADMAP project aims to deliver a series of methods and tools that will allow the scalable, transferable integration of data on patient outcomes in the real world. The tools will be developed and tested through pilot projects and will lay the foundations for a Europe-wide platform on real-world evidence in Alzheimer’s disease. The project will also actively engage with people living with dementia amongst other stakeholders and address the ethical, legal and social implications of adopting a real world evidence approach to Alzheimer’s disease.


  • The Chancellor, Masters and Scholars of the University of Oxford
  • National Institute for Health and Care Excellence
  • Erasmus Universitair Medisch Centrum Rotterdam
  • Universiteit Maastricht
  • Synapse Research Management Partners S.L
  • Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina
  • Københavns Universitet
  • Alzheimer Europe
  • University of Edinburgh
  • Goeteborgs Universitet
  • Aarhus Universitet
  • London School of Economics and Political Science
  • Agentschap College ter Beoordeling van Geneesmiddelen
  • IXICO Technologies Ltd
  • Rijksuniversiteit Groningen
  • Novartis Pharma AG
  • Eli Lilly and Company Ltd
  • Biogen
  • Hoffmann‐La Roche Ltd
  • Janssen Pharmaceutica NV
  • GE Healthcare Ltd
  • AC Immune SA
  • Takeda Development Centre Europe Ltd
  • H. Lundbeck A/S
  • Academisch Ziekenhuis Leiden – Leids Universitair Centrum